Nasus Pharma Ltd

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding: the Company’s expectations regarding its growth, the advancement of its clinical programs, and anticipated clinical and commercial milestones for NS002 and other product candidates; expectations regarding interim analyses, top-line data readouts, and future clinical milestones; plans and timelines for regulatory submissions and clinical milestones, including IND applications and potential regulatory approvals; expectations regarding the initiation and progression of pivotal and pediatric clinical studies; the potential safety, efficacy, pharmacokinetic profile, and clinical benefits of NS002 and other product candidates; the potential advantages, applications, and commercial viability of the Company’s proprietary Nasax powder technology; the ability to advance product candidates toward commercialization; expectations regarding collaborations, including anticipated benefits related to manufacturing, regulatory pathways, and supply chain capabilities; future pipeline development and plans to initiate first-in-human studies for additional candidates; and the Company’s strategy, business plans, objectives, and expectations for future growth, and value creation. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s prospectus filed with the U.S. Securities and Exchange Commission dated August 12, 2025. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.